Transcription Factor receives rights to NF-kappa B program

Anesiva (NASDAQ:ANSV) granted Transcription Factor Therapeutics (Irvine, Calif.) exclusive worldwide rights to its NF-kappa B decoy program, including Avrina, for up to $114 million in upfront and mil...